VivoSeq
Psychiatry

Bipolar Disorder

173

Pipeline Programs↗

21

Active Trials↗

61

Companies Involved↗

Bipolar Disorder is a highly competitive landscape with 173 programs across 61 companies. The most active players are Nobilis Therapeutics Inc., Bayer, Corcept Therapeutics. 75 therapies are approved with 28 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

78/100

Pipeline Velocity

25/100

Mech. Concentration

7/100

Completion Rate

83/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

Nobilis Therapeutics Inc.

1 program

Phase 1Bayer logo

Bayer

3 programs

Phase 2C

Corcept Therapeutics

1 program

Phase 2A

Autobahn Therapeutics, Inc.

1 program

Phase 2I

Iovance Biotherapeutics, Inc.

1 program

Phase 2N

Neurim Pharmaceuticals Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical31

Galantamine

Wim Janssens

Divalproex Sodium

Teva

Vraylar

AbbVie

Norepinephrine

General Hospital of Ningxia Medical University

Desvenlafaxine

Prism Pharmaceuticals

Phase 19

Candesartan

AstraZeneca

Dronabinol

Alnylam Pharmaceuticals

Xenon

Nobilis Therapeutics Inc.

Taurine

Third Military Medical University

Epidiolex

Jazz Pharmaceuticals

Phase 230

MCN36 (nutritional Supplement)

University of Calgary

Aldesleukin

Iovance Biotherapeutics, Inc.

Curcumin

Merck & Co.

Alcohol

Astellas

Infliximab

Organon and Co

Phase 328

Ketamine Hydrochloride

Boehringer Ingelheim

Dextromethorphan

Pfizer

Bifeprunox

Solvay Pharmaceuticals

Escitalopram

AbbVie

Tamoxifen Citrate

San Diego Pacific Oncology & Hematology Associates

Approved75

Semaglutide

Novo Nordisk

Risperidone

Wim Janssens

Pramipexole

Boehringer Ingelheim

Memantine

AbbVie

Topiramate

Wim Janssens

Analysis

Modality Breakdown

97%

Small molecule

181 of 187 classified programs — the dominant modality here.

3%ALL OTHERSPeptide42%Monoclonal antibody1<1%Protein / enzyme1<1%

Small molecule leads; the ring shows all 187 classified programs, each share of the total. Modality classified for 99% of 193 pipeline programs.

Analysis

Trial Status

234

clinical trials

Completed156 · 67%
Terminated25 · 11%
Unknown status24 · 10%
Recruiting14 · 6%
Withdrawn8 · 3%
Active, not recruiting4 · 2%
Other3 · 1%

Clinical Trials

Trial Activity

234 trials

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
Recruiting·TThe University of Texas Health Science Center, Houston·Phase 2·NCT06706232·10 enrolled
Effects of Lithium on Suicide Prevention in Adolescents and Young Adults With Bipolar Disorder in China
Recruiting·PPeking University·N/A·NCT06424613·600 enrolled
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
Recruiting·MMayo Clinic·Phase 4·NCT07213466·100 enrolled
Lithium Versus Lamotrigine in Bipolar Disorder, Type II
Recruiting·UUniversity Hospital Bispebjerg and Frederiksberg·Phase 4·NCT06184581·200 enrolled
ALTO-100 in Bipolar Disorder With Depression (BD-D)
Recruiting·—·Phase 2·NCT06656416·200 enrolled
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
Recruiting·BBioXcel Therapeutics Inc·Phase 1·NCT05025605·140 enrolled
Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder
Recruiting·MMclean Hospital·Phase 2·NCT05457465·25 enrolled
Correcting Circadian Rhythms to Breakthrough in Bipolar Disorder
Recruiting·—·Phase 2·NCT06226025·50 enrolled
A Study of Olanzapine in Participants With Bipolar Disorder.
Recruiting·Boryung Pharmaceutical Co., Ltd logoBoryung Pharmaceutical Co., Ltd·N/A·NCT07263191·3,000 enrolled
Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults
Recruiting·AAutobahn Therapeutics, Inc.·Phase 2·NCT06869187·35 enrolled
A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania With Mixed Features in Bipolar-I Disorder (BALSAM-3)
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT06929273·450 enrolled
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment With Brenipatide in Delaying Time to Relapse Compared With Placebo in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
Recruiting·Eli Lilly logoEli Lilly·Phase 2·NCT07286175·400 enrolled
NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder
Recruiting·National Institute of Mental Health (NIMH)·N/A·NCT05669703·1,260 enrolled
EMERGE-4: KarXT Adjunct in Bipolar Depression
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT06200001·500 enrolled
Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder
Active, not recruiting·—·N/A·NCT03336918·120 enrolled
Page 1 of 16

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)